US Patent

US8071623 — Amide substituted indazoles as poly(ADP-ribose)polymerase(PARP) inhibitors

Composition of Matter · Assigned to Istituto di Ricerche di Biologia Molecolare P Angeletti SpA · Expires 2031-03-27 · 5y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects compounds of formula I and their derivatives, which are inhibitors of poly(ADP-ribose)polymerase (PARP).

USPTO Abstract

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of poly (ADP-ribose) polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage, and as chemo- and/or radiosensitizers for cancer treatment.

Drugs covered by this patent

Patent Metadata

Patent number
US8071623
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-03-27
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Istituto di Ricerche di Biologia Molecolare P Angeletti SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.